Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/68934
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Cantley, M. | - |
dc.contributor.author | Bartold, P. | - |
dc.contributor.author | Marino, V. | - |
dc.contributor.author | Fairlie, D. | - |
dc.contributor.author | Le, G. | - |
dc.contributor.author | Lucke, A. | - |
dc.contributor.author | Haynes, D. | - |
dc.date.issued | 2011 | - |
dc.identifier.citation | Journal of Periodontal Research, 2011; 46(6):697-703 | - |
dc.identifier.issn | 0022-3484 | - |
dc.identifier.issn | 1600-0765 | - |
dc.identifier.uri | http://hdl.handle.net/2440/68934 | - |
dc.description.abstract | BACKGROUND AND OBJECTIVE: Bone loss caused by enhanced osteoclast activity is a significant feature of periodontitis. Histone deacetylase inhibitors (HDACi) can suppress osteoclast-mediated bone loss in vitro and in vivo. This study investigated whether HDACi can suppress bone loss in experimental periodontitis. MATERIAL AND METHODS: Experimental periodontitis was induced in mice by oral inoculation with Porphyromonas gingivalis bacteria. Mice were treated orally with olive oil alone, with olive oil and a novel compound – 1179.4b – which targets both Class I and Class II histone deacetylases (HDACs) or with olive oil and MS-275, which targets Class I HDACs. Micro-computed tomography scans of live mice, stereo imaging and histological analyses were used to detect changes in bone. RESULTS: In the absence of treatment there was a 13.2% increase in bone volume in controls compared with a 7.4% decrease in P. gingivalis-inoculated mice. 1179.4b significantly reduced bone loss, with a 3.4% increase in bone volume (p < 0.01). MS-275 did not have a significant effect on P. gingivalis-induced bone loss. Histological analysis revealed that 1179.4b reduced bone loss despite having no effect on inflammation. CONCLUSION: HDACi were found to effectively suppress bone loss in the mouse model of periodontitis. 1179.4b – the inhibitor of Class I and Class II HDACs – was more effective at suppressing bone loss than MS-275, which targets Class I HDACs only. These compounds may therefore have the potential to be used for the management of periodontitis. | - |
dc.description.statementofresponsibility | M. D. Cantley, P. M. Bartold, V. Marino, D. P. Fairlie, G. T. Le, A. J. Lucke, and D. R. Haynes | - |
dc.language.iso | en | - |
dc.publisher | Blackwell Munksgaard | - |
dc.rights | © 2011 John Wiley & Sons A/S | - |
dc.source.uri | http://dx.doi.org/10.1111/j.1600-0765.2011.01392.x | - |
dc.subject | Histone deacetylase inhibitor | - |
dc.subject | periodontitis | - |
dc.subject | osteoclasts | - |
dc.subject | bone resorption | - |
dc.title | Histone deacetylase inhibitors and periodontal bone loss | - |
dc.type | Journal article | - |
dc.identifier.doi | 10.1111/j.1600-0765.2011.01392.x | - |
dc.relation.grant | ARC | - |
pubs.publication-status | Published | - |
dc.identifier.orcid | Cantley, M. [0000-0002-7188-0928] | - |
dc.identifier.orcid | Bartold, P. [0000-0002-5695-3877] [0000-0002-6225-3084] | - |
Appears in Collections: | Aurora harvest 5 Dentistry publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.